Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Prescriber's Guide_ Stahl's Ess - Stephen M. Stahl.docx
Скачиваний:
1
Добавлен:
01.07.2025
Размер:
3 Мб
Скачать
☆

Desipramine: side effects How Drug Causes Side Effects

✽ Anticholinergic activity for desipramine may be somewhat less than for some other TCAs, yet can still explain the presence, if lower incidence, of sedative effects, dry mouth, constipation, and blurred vision

• Sedative effects and weight gain may be due to antihistamine properties

• Blockade of alpha adrenergic 1 receptors may explain dizziness, sedation, and hypotension

• Cardiac arrhythmias and seizures, especially in overdose, may be caused by blockade of ion channels

Notable Side Effects

• Blurred vision, constipation, urinary retention, increased appetite, dry mouth, nausea, diarrhea, heartburn, unusual taste in mouth, weight gain

• Fatigue, weakness, dizziness, sedation, headache, anxiety, nervousness, restlessness

• Sexual dysfunction, sweating

Life-Threatening or Dangerous Side Effects

• Paralytic ileus, hyperthermia (TCAs + anticholinergic agents)

• Lowered seizure threshold and rare seizures

• Orthostatic hypotension, sudden death, arrhythmias, tachycardia

• QTc prolongation

• Hepatic failure, extrapyramidal symptoms

• Increased intraocular pressure

• Blood dyscrasias

• Rare induction of mania

• Rare activation of suicidal ideation and behavior (suicidality) (short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo beyond age 24)

Weight Gain

• Many experience and/or can be significant in amount

• Can increase appetite and carbohydrate craving

Sedation

• Many experience and/or can be significant in amount

• Tolerance to sedative effects may develop with long-term use

What to Do About Side Effects

• Wait

• Wait

• Wait

• Lower the dose

• Switch to an SSRI or newer antidepressant

Best Augmenting Agents for Side Effects

• Many side effects cannot be improved with an augmenting agent

DESIPRAMINE: DOSING AND USE

Usual Dosage Range

• 100–200 mg/day (for depression)

• 50–150 mg/day (for chronic pain)

Dosage Forms

• Tablets 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg

How to Dose

• Initial 25 mg/day at bedtime; increase by 25 mg every 3–7 days

• 75 mg/day once daily or in divided doses; gradually increase dose to achieve desired therapeutic effect; maximum dose 300 mg/day

Dosing Tips

• If given in a single dose, should generally be administered at bedtime because of its sedative properties

• If given in split doses, largest dose should generally be given at bedtime because of its sedative properties

• If patients experience nightmares, split dose and do not give large dose at bedtime

• Patients treated for chronic pain may only require lower doses (e.g., 50–75 mg/day)

• Risk of seizure increases with dose

✽ Monitoring plasma levels of desipramine is recommended in patients who do not respond to the usual dose or whose treatment is regarded as urgent

• If intolerable anxiety, insomnia, agitation, akathisia, or activation occur either upon dosing initiation or discontinuation, consider the possibility of activated bipolar disorder, and switch to a mood stabilizer or an atypical antipsychotic

Overdose

• Death may occur, and may be more likely than with other TCAs; convulsions, cardiac dysrhythmias, severe hypotension, CNS depression, coma, changes in EKG

Long-Term Use

• Safe

Habit Forming

• No

How to Stop

• Taper to avoid withdrawal effects

• Even with gradual dose reduction some withdrawal symptoms may appear within the first 2 weeks

• Many patients tolerate 50% dose reduction for 3 days, then another 50% reduction for 3 days, then discontinuation

• If withdrawal symptoms emerge during discontinuation, raise dose to stop symptoms and then restart withdrawal much more slowly

Pharmacokinetics

• Substrate for CYP450 2D6 and 1A2

• Is the active metabolite of imipramine, formed by demethylation via CYP450 1A2

• Half-life approximately 24 hours

Drug Interactions

• Tramadol increases the risk of seizures in patients taking TCAs

• Use of TCAs with anticholinergic drugs may result in paralytic ileus or hyperthermia

• Fluoxetine, paroxetine, bupropion, duloxetine, and other CYP450 2D6 inhibitors may increase TCA concentrations

• Cimetidine may increase plasma concentrations of TCAs and cause anticholinergic symptoms

• Phenothiazines or haloperidol may raise TCA blood concentrations

• May alter effects of antihypertensive drugs; may inhibit hypotensive effects of clonidine

• Use of TCAs with sympathomimetic agents may increase sympathetic activity

• Methylphenidate may inhibit metabolism of TCAs

• Activation and agitation, especially following switching or adding antidepressants, may represent the induction of a bipolar state, especially a mixed dysphoric bipolar II condition sometimes associated with suicidal ideation, and require the addition of lithium, a mood stabilizer or an atypical antipsychotic, and/or discontinuation of desipramine

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]